HTRS Board of Directors


Shannon Carpenter, MD, MSShannon L. Carpenter, MD, MS

HTRS President
Associate Division Director, Kansas City Comprehensive Hemophilia Treatment Center
Section Chief of Hematology, Children's Mercy Hospital; Professor of Pediatrics, University of Missouri-Kansas City

Dr. Carpenter's clinical research interests include inhibitors in hemophilia patients and the risk for thrombosis in hospitalized pediatric patients. She serves on the Board of ATHN and is Deputy Editor of PREP Hematology/Oncology published online by the AAP.

Shannon MeeksShannon L. Meeks , MD

HTRS Vice President
Associate Professor of Pediatrics/Scientific Director for Hemostasis and Thrombosis
Emory University School of Medicine/The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Department of Pediatrics

Dr. Meeks has a basic, translational, and clinical research interest in the immune response in hemophilia A. Her laboratory in particular has characterized the epitopes recognized in the B-cell response to factor VIII.

A. Koneti Rao, MD, FACP, FAHA

HTRS Secretary
Sol Sherry Professor of Medicine, Thrombosis Research and Pharmacology, Clinical Pathology and Laboratory Medicine
Co-Director, Sol Sherry Thrombosis Research Center
Director, Benign Hematology, Hemostasis and Thrombosis, Lewis Katz School of Medicine, Temple University, Philadelphia PA

Dr. Rao's research focuses on the molecular mechanisms of inherited platelet disorders, diabetes mellitus and antithrombotic therapy. With more than 250 publications, he is also Associate Editor of Henry's Clinical Management by Laboratory, McPherson and Pinkus (Editors), 23rd Edition. He is a member of ASCI and has served on NIH study sections. 

Lynn Malec, MD, MSc

HTRS Treasurer
Medical Director, Comprehensive Center for Bleeding Disorders
Versiti/Medical College of Wisconsin

Dr. Malec is actively involved in the clinical care of both adult and pediatric patients with disorders of hemostasis and thrombosis as well as clinical research involving this patient population. She was awarded the 2016 HTRS/ATHN DREAM Award to explore the impact of extended half-life products in patients with hemophilia.                      

Rebecca Krause-JarresRebecca Kruse-Jarres, MD, MPH

HTRS Immediate Past President 
Director, Washington Center for Bleeding Disorders at Bloodworks Northwest 
Professor of Medicine and Pediatrics, University of Washington

In addition to regular clinical activity, Dr. Kruse-Jarres is internationally known for her work with inhibitors in acquired and congenital hemophilia and has been actively involved with national and international clinical trials studying new treatments for this patient population. 



Gowthami Arepally, MD

Professor of Medicine, Division of Hematology
Medical Director of Therapeutic Apheresis, Vice Chief of Research/Division of Hematology
Duke University Medical Center

Dr. Arepally's clinical interests lie in immune thrombocytopenias and thrombotic disorders. Current lab efforts focus on the role of complement activation in the immune and thrombotic complications of HIT, the role of complement in sickle cell alloimmunization, and complement therapeutics.

Wolfgang Bergmeier, PhD

Associate Professor of Biochemistry and Biophysics
University of North Carolina at Chapel Hill

Dr. Bergmeier is a biomedical researcher working in signal transduction, platelet biology, and hemostasis and thrombosis.  His lab research spans from Harvard Medical School to the Cardeza Foundation for Hematologic Research in Philadelphia to the University of North Carolina School of Medicine. His ongoing work focuses on better understanding small GTPase signaling in platelets and megakaryocytes.

Brian R. Branchford, MD

Assistant Professor of Pediatrics, University of Colorado Hemophilia and Thrombosis Center
Associate Program Director, Pediatric Hematology/Oncology Fellowship Program
Children’s Hospital Colorado

Dr. Branchford is a physician co-leader for local and national quality/process improvement efforts to develop safe and effective thromboprophylaxis strategies, and co-founded the Children’s Hospital-Acquired Thrombosis (CHAT) Clinical Research Consortium.  He also has a basic/translational science lab that focuses on the role of platelet activation signaling in thromboinflammation.

Deborah Siegal, MD, MSc, FRCPC

HTRS Canadian Representative
Associate Professor, Department of Medicine, Division of Hematology and Thromboembolism
McMaster University

A Canadian clinician and researcher in thrombosis medicine, Dr. Seigal has developed knowledge translation initatives in thrombosis medicine for the American College of Cardiology, Thrombosis Canada and the CanVECTOR Network.  Her goal is to improve cardiovascular outcomes by minimizing harm of anticoagulation in patients at high risk of bleeding.


Mary Cushman, MD, MSc

Professor of Medicine and Pathology
Medical Director, Thrombosis and Hemostasis Program
Board Director, Cardiovascular Research Institute, University of Vermont

Dr. Cushman's research focuses on causative factors for heart disease, stroke, cognitive impairment and venous thrombosis.  She completed two terms as Board Director for the American Heart Association in 2017 and is Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, ISTH's open-access journal.


Barbara C. Furie, PhD

Professor of Medicine, Emeritus
Beth Israel Deaconess Medical Center
Harvard University

Dr. Furie’s research career focused on hemostasis and thrombosis, with major areas of investigation including structure-function relationships of the blood coagulation proteins, study of the vascular cell adhesion molecule P-selectin, and the function of thiol isomerases in normal hemostasis and in thrombosis.  She has been active in many professional societies including ASH and ISTH, and her major commitment to NASTH led to the opportunity to participate with HTRS in the recent merger of the two societies.

Bryce Kerlin, MD

Professor of Pediatrics/Hematology
The Ohio State University College of Medicine Center
PI, Center for Clinical & Translational Research/The Abigail Wexner Research Institute, Nationwide Children's Hospital

Dr. Kerlin is Director of The Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children's Hospital and an Attending Physician for the Division of Pediatric Hematology/Oncology/BMT. His lab studies interactions between the coagulation and glomerular biology systems with the goal of improving care for persons with kidney disease.


Alan Mast, MD, PhD

Medical Director/Medical Services, Senior Investigator
Versiti/BloodCenter of Wisconsin
Associate Professor, Department of Pathology and of Cell Biology, Neurobiology and Anatomy/Medical College of Wisconsin

Dr. Mast holds the Walter A. Schroeder Endowed Chair for Blood Research and maintains basic science and clinical research programs. Specifically, his basic research investigates vascular biology and the physiology of blood coagulation, and his clinical research investigates iron metabolism and iron deficiency anemia.

Leslie Raffini, MD, MSCELeslie Raffini, MD, MSCE

Associate Professor of Pediatrics, Division of Hematology
Director of the Hemostasis and Thrombosis Center
Children’s Hospital of Philadelphia/University of Pennsylvania

Dr. Raffini's clinical and research interests are in bleeding and clotting disorders, with particular focus on anticoagulation in children with cardiac disease, thromboprophylaxis, and epidemiology of pediatric thrombosis.


Margaret V. Ragni, MD, MPH

Director, Hemophilia Center of Western Pennsylvania
Professor of Medicine and Clinical Translational Science, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center

Dr. Ragni's prospective cohort, observational, case-control studies, and novel drug trains were among the first multi-center NIH-funded studies in hemophilia/VWD.  She mentors pre- and post-doctoral trainees. Dr. Ragni received the Kenneth Brinkhous Research Award (NHF), Kenneth E. Schuit Educator Award (Pitt), G. David Roodman Mentoring Award (Pitt), Murray Thelin Research Award (NHF), Max Wintrobe Endowed Lectureship (Utah), and Research Leadership Award (NHF). 


Jordan Shavit, MD, PhD

Associate Professor of Pediatrics, Hemostasis/Thrombosis
C.S. Mott Children's Hospital, Michigan Medicine
University of Michigan Medical School

Dr. Shavit is a practicing pediatric hematologist who specializes in the care of children with diseases of the blood coagulation system. He has established genetic models in zebrafish currently being used for the development of novel therapeutics for diseases of coagulation. His research has been supported by the NIH, HTRS, and other foundations.

Alisa S. Wolberg, PhD

Professor, Department of Pathology and Laboratory Medicine
University of North Carolina School of Medicine

Dr. Wolberg's expertise is in physiologic and pathophysiologic mechanisms in hemostasis and thrombosis, including in vitro and in vivo models of bleeding and thrombotic disorders. Ongoing lab work includes studies on contributions of fibrin(ogen), factor XIII, and red blood cells to thrombosis, role of female hormones and oral contraceptives in venous thromboembolism, cancer-associated thrombosis, and clot quality in hemophilia and factor XI deficiency.